sra-9 Antibody

What is Scavenger Receptor A (SRA) and why is it important in immunological research?

Scavenger Receptor A (SRA, also known as CD204) functions as an innate pattern recognition receptor (PRR) primarily expressed on myeloid-origin cells, including dendritic cells (DCs) and macrophages. Its biological significance stems from its pleiotropic activities in both normal physiology and pathological conditions. This versatility is attributed to SRA's ability to interact with a broad spectrum of ligands and macromolecules . SRA has been identified as an important immunosuppressive regulator that dampens the immunostimulatory function of DCs in promoting T cell-mediated antitumor immunity. This regulatory role makes SRA an important target for antibody development in cancer immunotherapy research, as inhibiting this immunosuppressor may enhance DC functionality for T cell priming and improve DC-targeted cancer immunotherapies .

How does SRA expression vary across different cell types?

SRA is predominantly expressed on cells of myeloid origin, with significant expression on dendritic cells and macrophages. Notably, SRA serves as a phenotypic marker for alternatively activated or M2-like macrophages. The receptor is involved in the functional regulation of tumor-associated macrophages that promote cancer progression . Expression levels can vary based on cellular activation states and tissue microenvironments. In research settings, baseline expression should be established for each experimental model as expression patterns may differ between mouse models and human samples.

What methodologies are recommended for detecting SRA expression in research samples?

Multiple approaches can be employed to detect SRA expression in research samples:

• Immunoblotting (Western blot) analysis - As demonstrated in the research where DCs were treated with lentivirus encoding shRNA for SRA, followed by immunoblotting to confirm SRA downregulation

• Flow cytometry - Using fluorescently-labeled anti-SRA antibodies to quantify expression on cell surfaces

• Immunohistochemistry - For detection in tissue sections

• RT-PCR or qPCR - For measuring SRA mRNA expression levels

For optimal results, researchers should validate antibody specificity using appropriate controls, including SRA-knockout or SRA-silenced cells as negative controls .

How do antibodies against SRA affect dendritic cell function in cancer immunotherapy research?

Antibodies targeting SRA can significantly alter dendritic cell function by blocking the immunosuppressive effects of this receptor. Research has demonstrated that inhibition of SRA enhances the immunostimulatory activity of DCs following capture of chaperone vaccines such as hsp110-gp100 . Specifically, when SRA is blocked or downregulated:

• DCs show increased capacity to stimulate proliferation of antigen-specific CD8+ T cells

• Enhanced production of IFN-γ by activated T cells is observed

• Improved antigen presentation and processing capabilities develop

• DCs demonstrate superior ability to prime naïve T cells in vivo

These functional enhancements ultimately lead to stronger T cell-mediated antitumor immune responses, making SRA antibodies valuable tools in cancer immunotherapy research .

What is the relationship between SRA targeting and chaperone vaccines in cancer treatment research?

Research has demonstrated that strategic inhibition of SRA through antibodies or RNA interference approaches significantly enhances the immunogenicity of DCs that have captured chaperone vaccines. This enhanced immunogenicity translates to:

• Improved T cell activation and proliferation

• Enhanced cytokine production by antigen-specific T cells

• Superior tumor control in experimental models

• Prolonged survival in cancer-bearing mice

These findings indicate that combining SRA inhibition with chaperone vaccines represents a promising approach to improve cancer immunotherapy efficacy .

How does SRA inhibition affect the tumor microenvironment?

SRA inhibition or silencing leads to reprogramming of the tumor microenvironment in several key ways:

• Transcriptional upregulation of IFN-γ (ifng) in tumor tissues

• Increased presence of immune effector cells, including CD8+ T cells and natural killer (NK) cells

• Enhanced cytotoxic activity against tumor cells

• Elevated expression of IL-12 and other pro-inflammatory cytokines

• Increased cancer cell death as demonstrated by TUNEL assays

These changes collectively create a more immunostimulatory tumor microenvironment that facilitates immune-mediated tumor control. The shift towards Th1-dominant immunity, characterized by elevated IFN-γ levels, is particularly important for tumor suppression and elimination .

What RNA interference approaches have proven effective for studying SRA function?

Two primary RNA interference approaches have demonstrated efficacy in SRA research:

• Short hairpin RNA (shRNA):

  • Delivered via lentiviral vectors for stable SRA knockdown

  • Provides long-term silencing suitable for extended studies

  • Example protocol: DCs were treated with lentivirus encoding shRNA for SRA, followed by immunoblotting analysis to confirm downregulation

• Small interfering RNA (siRNA):

  • Complexed with biocompatible carriers such as chitosan for in vivo delivery

  • Offers more transient silencing with potential for repeated administration

  • Demonstrated to effectively reduce SRA expression on CD11c+ DCs both in vitro and in vivo

These approaches provide valuable alternatives to antibody-mediated blocking when studying SRA function, allowing researchers to examine the effects of receptor downregulation rather than just inhibition of ligand binding .

What protocols are recommended for evaluating the impact of SRA targeting on T cell activation?

Several experimental protocols have proven effective for evaluating how SRA targeting affects T cell activation:

• CFSE dilution assays:

  • Label antigen-specific T cells with CFSE

  • Co-culture with SRA-targeted DCs loaded with relevant antigens

  • Measure proliferation through flow cytometric analysis of CFSE dilution

  • Example: SRA-silenced DCs co-cultured with CFSE-labeled, gp100-specific CD8+ T cells showed enhanced T cell proliferation compared to control DCs

• In vivo T cell priming assays:

  • Adoptively transfer antigen-specific T cells (e.g., CD90.1+ Pmel cells)

  • Immunize recipient mice with SRA-targeted DCs loaded with antigen

  • Analyze T cell activation through intracellular cytokine staining (e.g., IFN-γ)

  • Flow cytometric analysis to quantify activated antigen-specific T cells

• In vivo CTL assays:

  • Immunize mice with SRA-targeted DCs presenting relevant antigens

  • Inject differentially CFSE-labeled target cells (peptide-pulsed) and control cells

  • Measure specific killing through flow cytometry analysis of remaining CFSE+ populations

These protocols allow comprehensive assessment of the functional impact of SRA targeting on both in vitro and in vivo T cell responses.

What experimental design is recommended for evaluating SRA antibody efficacy in cancer models?

A comprehensive experimental design for evaluating SRA antibody efficacy should include:

• Baseline characterization:

  • Confirm SRA expression in target tissues/cells

  • Validate antibody specificity and blocking efficiency

• In vitro functional assays:

  • DC antigen presentation capacity with/without SRA blockade

  • T cell activation and proliferation assays

  • Cytokine production measurements

• In vivo tumor challenge models:

  • Establish tumors prior to treatment (e.g., B16-gp100 melanoma)

  • Treatment groups should include: SRA antibody alone, chaperone vaccine alone, combination therapy, and appropriate controls

  • Monitor tumor growth, survival, and immune parameters

• Mechanistic assessment:

  • Immune cell depletion studies (e.g., CD8+ T cell depletion as in Figure 2F to determine relative contributions of immune cell subsets)

  • Analysis of tumor microenvironment changes (cytokine profiling, immune cell infiltration)

  • T cell functional assessment from tumor-draining lymph nodes and spleen

This comprehensive approach allows for thorough evaluation of both the efficacy and mechanisms of SRA antibody-based interventions in cancer models.

How should researchers interpret seemingly contradictory data regarding SRA function?

When encountering contradictory data regarding SRA function, researchers should consider:

• Context-dependent effects: SRA may exhibit different functions depending on the cellular context, disease model, and experimental conditions. For example, SRA functions differently in infectious disease models compared to cancer models.

• Methodology considerations: Different knockdown/knockout approaches or antibody clones may target different domains of SRA, potentially explaining functional discrepancies.

• Temporal dynamics: The timing of SRA targeting relative to disease progression or immune activation may influence outcomes.

• Compensation mechanisms: Long-term SRA inhibition may trigger compensatory upregulation of other scavenger receptors or immune regulatory pathways.

To reconcile contradictory findings, researchers should:

• Directly compare different antibody clones or inhibition strategies within the same experimental system

• Perform comprehensive time-course studies

• Assess potential off-target effects of inhibition approaches

• Consider the broader immune context, including the activation status of target cells and the disease microenvironment

What experimental controls are essential when evaluating SRA antibody specificity?

Essential controls for evaluating SRA antibody specificity include:

• Genetic controls:

  • SRA knockout cells/tissues as negative controls

  • SRA-overexpressing cells as positive controls

  • Isotype control antibodies to rule out non-specific effects

• Blocking controls:

  • Pre-absorption with recombinant SRA protein

  • Competitive binding assays with known SRA ligands

  • Concentration-dependent inhibition assessment

• Functional validation:

  • Parallel assessment with alternative SRA inhibition methods (e.g., siRNA)

  • Functional rescue experiments by SRA re-expression in knockout models

  • Cross-validation with multiple antibody clones targeting different SRA epitopes

• Cell type controls:

  • SRA-negative cell lines as negative controls

  • Assessment across multiple SRA-expressing cell types to confirm consistency

These comprehensive controls help ensure that observed effects are specifically attributable to SRA targeting rather than off-target or non-specific effects of the antibody .

How can researchers quantitatively assess changes in dendritic cell function following SRA targeting?

Researchers can quantitatively assess changes in DC function following SRA targeting through several approaches:

• T cell activation metrics:

  • Proliferation indices from CFSE dilution assays

  • Percentage of cytokine-producing T cells (e.g., IFN-γ+CD8+ T cells)

  • Expression levels of activation markers on T cells (e.g., CD25, CD69)

• Antigen presentation capacity:

  • Surface expression of MHC-I/II and co-stimulatory molecules (CD80, CD86)

  • Antigen processing efficiency using fluorescently labeled antigens

  • Cross-presentation assays with exogenous antigens

• Functional outputs:

  • Cytokine production profiles (e.g., IL-12, TNF-α)

  • In vivo priming efficiency (% and absolute numbers of antigen-specific T cells)

  • In vivo CTL assay results (specific killing percentage)

• Computational approaches:

  • Integrated analysis of multiple parameters using principal component analysis

  • Correlation analyses between DC phenotypic changes and functional outcomes

  • Predictive modeling of therapeutic responses based on DC functional metrics

The study results demonstrated quantitative assessment through measures like percentage of maximum P-selectin expression and IFN-γ production by activated T cells following interaction with SRA-silenced DCs .

How might SRA antibodies be integrated with other immunotherapeutic approaches?

SRA antibodies could enhance the efficacy of multiple immunotherapeutic approaches through complementary mechanisms:

• Combination with immune checkpoint inhibitors:

  • SRA inhibition enhances DC function while checkpoint inhibitors (e.g., anti-PD-1/PD-L1) reinvigorate exhausted T cells

  • This dual approach addresses both antigen presentation and effector phases of the immune response

• Adjuvant for cancer vaccines:

  • As demonstrated with chaperone vaccines (hsp110-gp100, hsp110-HER/Neu-ICD), SRA antibodies significantly enhance vaccine immunogenicity

  • This combination enhances DC activation and subsequent T cell responses

• Enhancer for adoptive cell therapies:

  • Pre-treatment of patient DCs with SRA antibodies could improve the expansion and activation of tumor-reactive T cells for adoptive transfer

  • Alternatively, SRA blockade in the recipient could enhance in vivo functionality of transferred cells

• Combination with immunostimulatory cytokines:

  • SRA inhibition coupled with cytokines that promote DC maturation and function (e.g., GM-CSF, IL-12) could synergistically enhance antitumor immunity

Research findings indicate these combinations might achieve synergistic reprogramming of the tumor microenvironment toward enhanced anti-tumor immunity .

What are the emerging technologies for studying SRA function beyond antibody approaches?

Several emerging technologies offer new insights into SRA function beyond conventional antibody approaches:

• CRISPR/Cas9 genome editing:

  • Precise genetic manipulation of SRA in primary cells

  • Generation of domain-specific mutations to dissect receptor function

  • In vivo CRISPR delivery for tissue-specific SRA targeting

• RNA-based therapeutics:

  • Advanced siRNA delivery systems using biocompatible carriers like chitosan

  • mRNA approaches for temporary modulation of SRA expression

  • These approaches were validated in the research showing that chitosan-siRNA complexes efficiently reduced SRA expression on CD11c+ DCs both in vitro and in vivo

• Single-cell analysis platforms:

  • Single-cell RNA sequencing to examine heterogeneity in SRA expression and function

  • Mass cytometry for high-dimensional analysis of SRA+ cell populations and their functional states

• Computational approaches:

  • Systems biology modeling of SRA signaling networks

  • Artificial intelligence algorithms to predict optimal SRA targeting strategies

These technologies offer complementary approaches to studying SRA function and may lead to novel therapeutic strategies beyond conventional antibody targeting .

What insights from basic SRA research can guide the development of more effective therapeutic antibodies?

Basic research on SRA has revealed several insights that can guide the development of more effective therapeutic antibodies:

• Functional domains: Understanding which SRA domains are critical for immunosuppressive functions versus other physiological roles could enable development of domain-specific antibodies with improved therapeutic profiles.

• Signaling mechanisms: Research into how SRA mediates its immunosuppressive effects on DCs can identify whether antibodies should target receptor-ligand interactions or downstream signaling events.

• Cell type specificity: The observed roles of SRA in different myeloid cell populations (DCs vs. macrophages) suggests that antibodies with selective biodistribution profiles might enhance therapeutic efficacy while reducing off-target effects.

• Temporal considerations: Findings that SRA inhibition enhances vaccine-induced responses suggests that timing of SRA antibody administration relative to other immunotherapies is critical for optimal efficacy.

The research demonstrating that SRA silencing enhances DC immunogenicity and improves antitumor immunity provides a strong rationale for developing therapeutic antibodies targeting this receptor, particularly in combination with other cancer immunotherapies .